Status:
COMPLETED
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Lead Sponsor:
Organon and Co
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18-79 years
Phase:
PHASE3
Brief Summary
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40). After 6 weeks of treatment, the percent reduction in low-de...
Eligibility Criteria
Inclusion
- Participants who are either statin naive or on approved lipid lowering therapy for 6 weeks prior to study initiation
- Participant meets Adult Treatment Panel (ATP) III High Risk criteria
Exclusion
- Females who are pregnant or breastfeeding
- Participant consumes more than 14 alcoholic beverages per week
- Participant has been treated with an investigational drug within the last 30 days
- Participant has congestive heart failure (New York Heart Association \[NYHA\] Type III or IV)
- Participant has had gastric bypass
- Participant is newly diagnosed with type 1 or 2 diabetes
- Participant is Human Immunodeficiency Virus (HIV) positive
- Participant has a history of drug or alcohol abuse within the last 5 years
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00782184
Start Date
November 1 2008
End Date
September 1 2010
Last Update
May 16 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.